Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O95602
UPID:
RPA1_HUMAN
Alternative names:
A190; DNA-directed RNA polymerase I largest subunit; DNA-directed RNA polymerase I subunit A; RNA polymerase I 194 kDa subunit
Alternative UPACC:
O95602; B7Z7T0; D6W5M0; Q0VG05; Q9UEH0; Q9UFT9
Background:
DNA-directed RNA polymerase I subunit RPA1, also known as A190, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is the largest and catalytic core component of RNA polymerase I, primarily responsible for synthesizing ribosomal RNA precursors. This protein, together with the second largest subunit, forms the polymerase active center, crucial for the transcription process.
Therapeutic significance:
RPA1's involvement in Acrofacial dysostosis, Cincinnati type, a disorder affecting craniofacial and limb development, underscores its potential as a therapeutic target. Understanding the role of DNA-directed RNA polymerase I subunit RPA1 could open doors to potential therapeutic strategies.